Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
Total Valuation
Chemomab Therapeutics has a market cap or net worth of $11.94M. The enterprise value is $9.28M.
Market Cap$11.94M
Enterprise Value$9.28M
Share Statistics
Chemomab Therapeutics has 6,155,117 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,155,117
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Chemomab Therapeutics’s return on equity (ROE) is -1.03 and return on invested capital (ROIC) is -105.46%.
Return on Equity (ROE)-1.03
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-105.46%
Return on Capital Employed (ROCE)-1.07
Revenue Per Employee0.00
Profits Per Employee-700.56K
Employee Count20
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Chemomab Therapeutics is ―. Chemomab Therapeutics’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio2.40
Price to Fair Value2.40
Price to FCF-2.11
Price to Operating Cash Flow0.00
PEG Ratio0.04
Income Statement
In the last 12 months, Chemomab Therapeutics had revenue of 0.00 and earned -13.95M in profits. Earnings per share was -3.12.
Revenue0.00
Gross Profit-53.25K
Operating Income-14.74M
Pretax Income-13.95M
Net Income-13.95M
EBITDA-13.96M
Earnings Per Share (EPS)-3.12
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Chemomab Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change-76.13%
50-Day Moving Average2.66
200-Day Moving Average3.91
Relative Strength Index (RSI)30.26
Average Volume (3m)207.96K
Important Dates
Chemomab Therapeutics upcoming earnings date is Mar 11, 2026, Before Open (Confirmed).
Last Earnings DateNov 20, 2025
Next Earnings DateMar 11, 2026
Ex-Dividend Date―
Financial Position
Chemomab Therapeutics as a current ratio of 4.98, with Debt / Equity ratio of 0.00%
Current Ratio4.98
Quick Ratio4.98
Debt to Market Cap<0.01
Net Debt to EBITDA0.41
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Chemomab Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Chemomab Therapeutics EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -1.74.
EV to Sales0.00
EV to EBITDA-1.92
EV to Free Cash Flow-1.74
EV to Operating Cash Flow-1.73
Balance Sheet
Chemomab Therapeutics has $10.06M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.06M billion.
Cash & Marketable Securities$10.06M
Total Debt$0.00
Net Cash$10.06M
Net Cash Per Share$1.63
Tangible Book Value Per Share$3.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Chemomab Therapeutics is $17.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.50
Price Target Upside821.05% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast53.19%